In pts undergoing hip or knee arthroplasty for OA, aspirin (3.45%) compared with enoxaparin (1.82%) resulted in a significantly higher rate of symptomatic VTE within 90 days, defined as below- or above-knee DVT or pulmonary embolism https://t.co/7hgLbynNx6 https://t.co/HMc4UbMcdy

RA-ILD takes centre stage Greg McDermott presented abstract 2248 on the prevalence and mortality of subpleural interstitial lung abnormalities (ILA) in RA and non-RA comparators. https://t.co/zrg7IEhBfg https://t.co/dKACCzr4CZ

More Than a Conference:Life’s Lessons By: @KDAO2011 This is my 20th year attending the ACR meeting; despite my virtual attendance, I was still able to connect w/people. I reflected on my experiences w/ the conference and wanted to share my life lessons. https… https://t.co/9gBbaYBujc

MTX side effects more prominent in PsA than RA pts. Study of 240 PsA & 86108 RA pts starting either MTX or TNFi. TNFi AE same betw PsA & RA, but MTX adverse greater in PsA (44.8% vs. 29.4%), especially N/V, abdominal pain, depression, tinnitus https://t.co/0QBc6sb900 https://t.co/FZibAeFDBx

Sleep Quality & PsA Abstract #0387 presented at #ACR22 attempted to shed light in this important quality of life determinant. 247 adult PsA patients were included in this study and their sleep quality was measured using the PSQI questionnaire. https://t.co/lLTnrh2yxG https://t.co/9ViEnEFE6c

Humira biosimilars became available in EU 10/18; and will soon be available in the USA w/ Amjevita (Amgen) available Jan 2023 & 6 others (Pfizer, BI, Samsung, Coherus, Sandoz, Biocon) after July 2023. https://t.co/LH3MpT0o9O https://t.co/VeCbcdq5Ie

Methotrexate + pegloticase increases response rates in gout Patients with refractory gout and those with high burden of tophi have only few options when it comes to uric acid lowering agents. https://t.co/8cqsAXuzIB https://t.co/OSpf5ehiCm

Best of ACR Day Two in PSA https://t.co/FXGCPaTGX6 https://t.co/WICtjVICC2

PET CT Imaging to Define Risk of Progression from PSO to PsA Dr. Peter Nash ( @drpnash) discusses Abstract 1018 at #ACR22 Convergence. https://t.co/Wk3ibuh9ip https://t.co/FcLjDMJCgr

Low-grade Proteinuria in Non Renal Lupus: Should We be Worried? Dr. Yuz Yusof ( @Yuz6Yusof) discusses Abstract 1463 presented at #ACR22 https://t.co/v5fHfwvapv https://t.co/zf2kJy23r2

Opioid use in PsA and SpA Dr. Eric Dein discusses Abstract 1012 at ACR22 Convergence https://t.co/Doxbk7qW33 https://t.co/2UX07T2JpS

CAR-T Therapies in Antiphospholipid Antibody Syndrome Dr. Putman and Dr. Konig discuss abstract 1677 at ACR22 Convergence. Abstract 1677: Chimeric Autoantigen-T Cell Receptor (CATCR)-T Cell Therapies to Selectively Target Autoreactive B Cells https://t.co/VeAgl3qz8J https://t.co/rN4ZLM5Ft8